TOKYO, Nov 15, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be ...

few more so than Eisai, which is developing a package of products and services in Japan for people living with dementia. Its latest venture is an alliance with Tokyo-based Lifenet Insurance Co ...

Eisai's digital tool to allow self-assessment of cognitive performance – NouKNOW – will be used in a Japanese project aimed ... be deployed in Bunkyo City, Tokyo in a dementia monitoring ...

TOKYO (Kyodo) -- A single course of newly approved ... the treatment in Japan of early symptomatic Alzheimer's disease.

Tokyo, Nov. 13 (Jiji Press)--Japan's Central Social Insurance Medical Council, which advises the health minister, approved ...

Eisai Co., Ltd. and Eisai’s corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan. Read More on ESALF: Eisai NewsMORE Related Stocks Indices Commodities ...

Japanese stocks are higher in morning trade, led by gains in tech and real-estate stocks. Concerns about funding costs ease following the Fed’s rate cut overnight. Recruit Holdings is up 3.7% and ...

Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be broadcast nationwide in Japan from November 15 with the aim of increasing public ...